Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-95266 in Relapsed and/or Refractory Multiple Myeloma
NCT04674813Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GPRC5D-directed CAR T cells in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Number of participants with Adverse Events at 2 years, Number of participants with significant laboratory abnormalities at 2 years and 3 more. Started Feb 2021; status: completed.
02
Drugs
GPRC5D-directed CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04674813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674813.